These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 18802099)

  • 1. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice.
    Forbes EK; Sander C; Ronan EO; McShane H; Hill AV; Beverley PC; Tchilian EZ
    J Immunol; 2008 Oct; 181(7):4955-64. PubMed ID: 18802099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara.
    Goonetilleke NP; McShane H; Hannan CM; Anderson RJ; Brookes RH; Hill AV
    J Immunol; 2003 Aug; 171(3):1602-9. PubMed ID: 12874255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using a prime and pull approach, lentivector vaccines expressing Ag85A induce immunogenicity but fail to induce protection against Mycobacterium bovis bacillus Calmette-Guérin challenge in mice.
    Britton G; MacDonald DC; Brown JS; Collins MK; Goodman AL
    Immunology; 2015 Oct; 146(2):264-70. PubMed ID: 26095282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterologous Boost Following
    Wu Y; Cai M; Ma J; Teng X; Tian M; Bassuoney EBMB; Fan X
    Front Immunol; 2018; 9():2439. PubMed ID: 30425711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and protective efficacy of prime-boost regimens with recombinant (delta)ureC hly+ Mycobacterium bovis BCG and modified vaccinia virus ankara expressing M. tuberculosis antigen 85A against murine tuberculosis.
    Tchilian EZ; Desel C; Forbes EK; Bandermann S; Sander CR; Hill AV; McShane H; Kaufmann SH
    Infect Immun; 2009 Feb; 77(2):622-31. PubMed ID: 19064635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol vaccination with AERAS-402 elicits robust cellular immune responses in the lungs of rhesus macaques but fails to protect against high-dose Mycobacterium tuberculosis challenge.
    Darrah PA; Bolton DL; Lackner AA; Kaushal D; Aye PP; Mehra S; Blanchard JL; Didier PJ; Roy CJ; Rao SS; Hokey DA; Scanga CA; Sizemore DR; Sadoff JC; Roederer M; Seder RA
    J Immunol; 2014 Aug; 193(4):1799-811. PubMed ID: 25024382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intranasal boosting with an adenovirus-vectored vaccine markedly enhances protection by parenteral Mycobacterium bovis BCG immunization against pulmonary tuberculosis.
    Santosuosso M; McCormick S; Zhang X; Zganiacz A; Xing Z
    Infect Immun; 2006 Aug; 74(8):4634-43. PubMed ID: 16861651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.
    Lu J; Wang C; Zhou Z; Zhang Y; Cao T; Shi C; Chen Z; Chen L; Cai C; Fan X
    Clin Dev Immunol; 2011; 2011():617892. PubMed ID: 21461375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis.
    Majlessi L; Simsova M; Jarvis Z; Brodin P; Rojas MJ; Bauche C; Nouzé C; Ladant D; Cole ST; Sebo P; Leclerc C
    Infect Immun; 2006 Apr; 74(4):2128-37. PubMed ID: 16552042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved protection against tuberculosis after boosting the BCG-primed mice with subunit Ag 85a delivered through intact skin with deformable vesicles.
    Kumar G; Sharma N; Gupta P; Joshi B; Gupta UD; Cevc G; Chopra A
    Eur J Pharm Sci; 2016 Jan; 82():11-20. PubMed ID: 26522817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
    Romano M; D'Souza S; Adnet PY; Laali R; Jurion F; Palfliet K; Huygen K
    Vaccine; 2006 Apr; 24(16):3353-64. PubMed ID: 16488518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A.
    Beverley P; Ronan E; Lee L; Arnold I; Bolinger B; Powrie F; Tchilian E
    Vaccine; 2013 Feb; 31(7):1086-93. PubMed ID: 23262169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal administration of Ag85B-ESAT-6 protects against infection with Mycobacterium tuberculosis and boosts prior bacillus Calmette-Guerin immunity.
    Dietrich J; Andersen C; Rappuoli R; Doherty TM; Jensen CG; Andersen P
    J Immunol; 2006 Nov; 177(9):6353-60. PubMed ID: 17056566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice.
    Aldwell FE; Tucker IG; de Lisle GW; Buddle BM
    Infect Immun; 2003 Jan; 71(1):101-8. PubMed ID: 12496154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Immunogenicity and Protective Efficacy Elicited by Mycobacterium bovis BCG Overexpressing Ag85A Protein against Mycobacterium tuberculosis Aerosol Infection.
    Xu ZZ; Chen X; Hu T; Meng C; Wang XB; Rao Y; Zhang XM; Yin YL; Pan ZM; Jiao XA
    Front Cell Infect Microbiol; 2016; 6():3. PubMed ID: 26858942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis.
    Hwang SA; Kruzel ML; Actor JK
    Int Immunopharmacol; 2005 Mar; 5(3):591-9. PubMed ID: 15683854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved immunogenicity of recombinant Mycobacterium bovis bacillus Calmette-Guérin strains expressing fusion protein Ag85A-ESAT-6 of Mycobacterium tuberculosis.
    Deng YH; Sun Z; Yang XL; Bao L
    Scand J Immunol; 2010 Oct; 72(4):332-8. PubMed ID: 20883318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
    Badell E; Nicolle F; Clark S; Majlessi L; Boudou F; Martino A; Castello-Branco L; Leclerc C; Lewis DJ; Marsh PD; Gicquel B; Winter N
    Vaccine; 2009 Jan; 27(1):28-37. PubMed ID: 18977269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen.
    Santosuosso M; Zhang X; McCormick S; Wang J; Hitt M; Xing Z
    J Immunol; 2005 Jun; 174(12):7986-94. PubMed ID: 15944305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.